Abstract:The deficits in Alzheimer disease (AD) stem at least partly from neurotoxic beta-amyloid peptides generated from the amyloid precursor protein (APP). APP may also be cleaved intracellularly at Asp664 to yield a second neurotoxic peptide, C31. Previously, we showed that cleavage of APP at the C-terminus is required for the impairments seen in APP transgenic mice, by comparing elements of the disease in animals modeling AD, with (platelet-derived growth factor B-chain promoter-driven APP transgenic mice; PDAPP) versus without (PDAPP D664A) a functional Asp664 caspase cleavage site. However, the signaling mechanism(s) by which Asp664 contributes to these deficits remains to be elucidated. In this study, we identify a kinase protein, recently shown to bind APP at the C-terminus and to contribute to AD, whose activity is modified in PDAPP mice, but normalized in PDAPP D664A mice. Specifically, we observed a significant increase in nuclear p21-activated kinase (isoforms 1, 2, and or 3; PAK1/2/3) activation in hippocampus of 3 month old PDAPP mice compared with non-transgenic littermates, an effect completely prevented in PDAPP D664A mice. In contrast, 13 month old PDAPP mice displayed a significant decrease in PAK-1/2/3 activity, which was once again absent in PDAPP D664A mice. Similarly, in hippocampus of early and severe AD subjects, there was a progressive and subcellular-specific reduction in active PAK-1/2/3 compared with normal controls. Interestingly, total PAK-1/2/3 protein was increased in early AD subjects, but declined in moderate AD and declined further, to significantly below that of control levels, in severe AD. These findings are compatible with previous suggestions that PAK may be involved in the pathophysiology of AD, and demonstrate that both early activation and late inactivation in the murine AD model require the cleavage of APP at Asp664.

Delta-Secretase Phosphorylation by SRPK2 Enhances Its Enzymatic Activity, Provoking Pathogenesis in Alzheimer's Disease

Srpk2 Phosphorylates Tau and Mediates the Cognitive Defects in Alzheimer'S Disease

Delta-secretase Cleaves Amyloid Precursor Protein and Regulates the Pathogenesis in Alzheimer's Disease

Delta- and Beta-Secretases Crosstalk Amplifies the Amyloidogenic Pathway in Alzheimer's Disease

Delta- and beta- secretases crosstalk amplifies the amyloidogenic pathway in Alzheimer’s disease

TrkB receptor cleavage by delta-secretase abolishes its phosphorylation of APP, aggravating Alzheimer’s disease pathologies

β2 Adrenergic Receptor, Protein Kinase A (PKA) and c-Jun N-terminal Kinase (JNK) Signaling Pathways Mediate Tau Pathology in Alzheimer Disease Models

[P4–126]: Δ‐secretase–cleaved TAU STIMULATES Aβ PRODUCTION VIA ACTIVATING STAT1‐BACE1 PATHWAY IN ALZHEIMER's DISEASE

Delta-secretase Triggers Alzheimer's Disease Pathologies in Wild-Type Happ/hmapt Double Transgenic Mice.

Δ-Secretase-cleaved Tau Stimulates Aβ Production Via Upregulating STAT1-BACE1 Signaling in Alzheimer's Disease.

Δ-Secretase in Neurodegenerative Diseases: Mechanisms, Regulators and Therapeutic Opportunities

Spatiotemporal Activation Of The C/Ebp Beta/Delta-Secretase Axis Regulates The Pathogenesis Of Alzheimer'S Disease

Delta-secretase-cleaved Tau Antagonizes TrkB Neurotrophic Signalings, Mediating Alzheimer’s Disease Pathologies

Dual-specificity tyrosine phosphorylation-regulated kinase 1A promotes the inclusion of amyloid precursor protein exon 7

The Synaptic Vesicle Protein 2a Interacts with Key Pathogenic Factors in Alzheimer’s Disease: Implications for Treatment

The Role and Mechanism of TPK‐SENP1 Signaling Axis in Regulating Aβ Deposition in Alzheimer’s Disease

C/EBPβ Regulates Delta-Secretase Expression and Mediates Pathogenesis in Mouse Models of Alzheimer’s Disease

Signal transduction in Alzheimer disease: p21-activated kinase signaling requires C-terminal cleavage of APP at Asp664.

Amyloid-β Precursor Protein Facilitates the Regulator of Calcineurin 1-Mediated Apoptosis by Downregulating Proteasome Subunit Α Type-5 and Proteasome Subunit Β Type-7.

CCAAT-Enhancer Binding Protein-beta (C/EBPP) Regulates Deltasecretase Expression, Mediating the Pathogenesis in Alzheimer's Disease

Inhibition of PKCδ reduces amyloid-β levels and reverses Alzheimer disease phenotypes